

# Ramon Andrade de Mello

[ramondemello@gmail.com](mailto:ramondemello@gmail.com)

• +55 (11) 950835698

<https://www.linkedin.com/in/ramon-andrade-de-mello-md-phd-facp-051a22160/?originalSubdomain=pt/> • São Paulo, Brazil



## Curriculum Vitae

Driven and highly accomplished professional with expertise in senior leadership, organizational strategy, operational planning, transformations, and financial performance in healthcare setting. Well-versed in engagement, cross-functional collaboration, business planning, capacity planning, business valuation and research. Highly-analytical with ability to deliver local and national priorities while meeting performance standard and organizational objectives. Key skills in project development, service improvement, business cases, clinical trials, scientific integrity, and medical responsibility. Knowledge of immuno-oncology, chemotherapy, targeted therapies, synthetic lethality and cancer epigenetics.

## Qualifications Summary

- Birthdate: 12.11.1979 | Gender: Male | Birthplace: Brazil | Civil Status: single | Nationalities: Portugal and Brazil
- Engaging communicator fluent in English (C1), Portuguese (C2), Italian (B2), and French (A2).
- Strong ability to build productive and strategic relationships with stakeholders, teams, and colleagues.
- Keen ability to analyze, interpret, and present clinical study data.
- Technical Proficiencies: Apple, Microsoft Office, Endnote X7, and SPSS 22.0.

## Education and Credentials

### Ph.D. in Medicine and Molecular Oncology

University of Porto, Porto, Portugal

*Thesis: The role of genetic polymorphisms in the angiogenesis pathways on the risk and prognosis of non-small cell lung cancer.*

### Master of Business Administration in Executive Management of Clinics, Hospital, and Health Industries

Getulio Vargas Foundation, Campus Paulista, São Paulo, Brazil

### PG Diploma in Medicine and Molecular Oncology

University of Porto, Portugal

### Medical Degree

Federal University of Ceara, Brazil

Ordem dos Medicos—Portugal, Full Registration, #44618 | CRM-SP—Brazil, Full Registration, #181245  
UK Full Registration, #GMC 7436909 | Board Certification in Medical Oncology | Fellow, American College of Physicians  
Medical Training in Medical Oncology at Instituto Portuguese de Oncologia Francisco Gentil  
Certification in Medical Oncology, European Society of Medical Oncology | Fellowship in Immunohemotherapy  
Clinical Research Fellowship, Royal Marsden NHS Foundation Trust | Internship in General Medicine  
Fellowship in General Ultrasound | Practice and Theory Course in Gynecologic and Obstetric Ultra-Sonography

## Professional Experience

Instruct undergraduate/graduate students in medical oncology, healthcare, medical education, clinical investigation, and business management topics. Serve as Director for Precision Oncology and Health Economics Research Group, execute international academic interchange programme, and oversee lung/skin outpatient clinics. Act as Editorial Board Member of Translational Lung Cancer Research, Cancers, Journal of Clinical Medicine, Oncology Reviews, PLoS ONE, and Rare Tumors. Serve as Scientific Reviewer for several journals, including Journal of Cancer Research and Clinical Oncology and Journal of Thoracic Oncology. Cultivate trusting relationships with patients, colleagues, stakeholders, and team members.

- Professor, Research Supervisor and Chief of medical oncology discipline at Nine of July University, São Paulo, Brazil, from 2018.
- Consultant Medical Oncologist/Clinical Lead, Nine of July Hospital, São Paulo, Brazil, since 2018.
- Invited Academic Professor of Medical Oncology at University of Algarve, Portugal, from 2015 to 2022.
- Hon Assistant Professor of Medicine at Faculty of Medicine, University of Porto, Portugal, from 2010 to 2020.
- Consultant Medical Oncologist for Hospital Sao Mateus, Brazil, from 2015 to 2018.
- Locum Consultant Medical Oncologist at Clatterbridge Cancer Centre, UK, in 2017.
- Locum Consultant Medical Oncologist, Edinburg Cancer Centre, UK, from 2016 to 2017.
- Medical Oncologist at Portuguese Oncology Institute, Portugal, in 2015.
- Fellowship and CCT in medical oncology, 2007 to 2015.
- Emergency Department Physician, Brazil, from 2004 to 2006.

## Most Recent Professional Development

1. Member's reception, Royal Society of Medicine, London, UK, 10<sup>th</sup> July 2023
2. Annual Meeting of Fellows, Royal Society of Medicine, London, UK, 27<sup>th</sup> June 2023
3. ESMO advanced course programme: diagnostic and therapeutic application of nuclear medicine in oncology, Essen, Germany, 19-20 May 2023
4. CSTF Equality, Diversity and Human Rights, Oxford University Hospitals NHS Foundation Trust, Oxford, 18<sup>th</sup> May 2023
5. CSTF Moving and Handling Level 2 (Theory)\_Moving and Handling - Level 2 (Theory) Oxford University Hospitals NHS Foundation Trust, Oxford, 18<sup>th</sup> May 2023
6. CSTF Health, Safety and Welfare, Oxford University Hospitals NHS Foundation Trust, Oxford, 18<sup>th</sup> May 2023
7. CSTF Health, Safety and Welfare, Oxford University Hospitals NHS Foundation Trust, Oxford, 17<sup>th</sup> May 2023
8. ESMO advanced course programme: precision oncology across tumours: tumour-agnostic and tumour-modulated (MSI and TMB, NTRK, BRAF, HRD), Lisbon, Portugal, 5 – 6 May 2023
9. Current trends in sarcoma management, Royal Society of Medicine, London, Sat 25 Mar 2023 9:45am to 5:20pm, 2023 (6 CPD)
10. Anaesthesia and cancer care, Royal Society of Medicine, London, 22<sup>th</sup> March 2023 (1 CPD)

11. Induction Training, Oxford University Hospital NHS Foundation Trust, Oxford, 26<sup>th</sup> October 2022 to 8<sup>th</sup> November 2022
12. Introduction to Good Clinical Practice (GCP) eLearning, National Institute for Health Care and Research, UK, 30<sup>th</sup> October 2022
13. 7th Latin American Masterclass in Clinical Oncology, European School of Oncology (ESO), 2-3 April 2022
14. Induction course, HCOR (Heart Hospital), 16th November 2020, São Paulo, Brazil
15. ESMO Virtual Preceptorship on Prostate Cancer 15 October 2020
16. ESMO Academy 2020 Virtual Meeting, 21 – 22 August 2020.
17. Advanced Cardiac Life Support Training, National Health Care Provider Solutions, Las Vegas, USA, 1st July 2020.
18. Intersections: advances in precision oncology, Sirio Libanes Hospital and Memorial Sloan Katering Cancer Center, 30<sup>th</sup> and 31<sup>st</sup> October, 2019, São Paulo, SP, Brazil.
19. Astellas Oncology Forum, 5th October 2019, Four Seasons Hotel São Paulo, São Paulo, Brazil.
20. X Board Review in medical oncology, Albert Einstein Israelite Hospital, 14<sup>th</sup> to 17<sup>th</sup> August 2019, São Paulo, Brazil.
21. Teach-in - acute medicine - Mersey region. Royal College of Physicians of London. Liverpool Medical Institution, Liverpool, UK, 4th April 2017. 2 CPD credits (ref 111568).
22. Conflicts resolution training course. Clatterbridge Cancer Center, 8 March 2017, Wirral, United Kingdom.
23. Basic Life Support and Resuscitation course. Templars Medical/Healthier Business group, CPD provider 50079, 25 January 2017, United Kingdom.
24. ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers. Swiss Chamber. Milano, Italy, 25 – 27 November 2016.
25. COSHH; Equality, Diversity and Inclusion; Fire Safety; First Aid in the Workplace; Food Hygiene; Handling violence, aggression and complaints; Health & Safety and Falls Prevention; Infection Control; Information Governance Incl. Record Keeping & Caldicott Protocols; Lone Worker, Manual Handling; RIDDOR; SOVA & SOCA Level 3. Templars Medical/Healthier Business group, CPD provider 50079, 30 October 2016, United Kingdom.
26. Oncomaster Meeting II, sponsored by Astrazeneca, Hotel Sheraton, Rio de Janeiro, Brazil, 29 – 30 April 2016.

27. Training at the MK3475 KEYNOTE 042 Latin American Region Investigator Meeting held 19 March 2016, Buenos Aires, Argentina.
28. Rectal Cancer Meeting Lisbon, 1st international edition. Hospital da Luz, Lisbon, Portugal, 25 - 26 June 2015.

## Most Recent Publications in International Science and Indexed Journals

1. de Mello RA, Perez KR, Haris PA. What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers? *Immunotherapy*. 2024 Apr 30. doi: 10.2217/imt-2024-0030. Online ahead of print.
2. Bruno FP, Degani-Costa LH, Global VAP Investigators. Medical Trainees' Knowledge and Attitudes Towards Electronic Cigarettes and Hookah: A Multinational Survey Study. *Respir Care* 2024 Feb 28;69(3):306-316. doi: 10.4187/respcare.11042.
3. De Mello RA, Roque K, Vazquez TP. Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer. *Immunotherapy* 2024 Mar;16(4):257-266. Doi: 10.2217/imt-2022-0277.
4. Degani-Costa LH, Bruno FP, Gushken F, Szlejf C, Tokeshi AB, Tehrani YF, Kaufman D, Prasad KKL, Kumar PSS, Jamir L, Benesch MGK, Ryan MG, Lotay H, Fuld JP, Fidalgo TM; Global Vaping Study investigators. Vaping and Hookah, De Mello RA. Use Among Medical Trainees: A Multinational Survey Study. *Am J Prev Med*. 2023 May 11: S0749-3797(23)00231-3. doi: 10.1016/j.amepre.2023.05.009. Epub ahead of print. PMID: 37178979.
5. Roque K, Ruiz R, Otoyá-Fernández I, Galarreta J, Vidaurre T, de Mello RA, Neciosup S, Mas L, Gómez H. The impact of telemedicine on cancer care: real-world experience from a Peruvian institute during the COVID-19 pandemic. *Future Oncol*. 2022 Oct;18(31):3501-3508. doi: 10.2217/fon-2022-0239. Epub 2022 Nov 11. PMID: 36367446.
6. Xie K, Feng J, Fan D, Wang S, Luo J, Ren Z, Zheng C, Diao Y, De Mello RA, Tavolari S, Brandi G, Roden AC, Ren B, Shen Y, Xu L. *BARX2/FOXA1/HK2* axis promotes lung adenocarcinoma progression and energy metabolism reprogramming. *Transl Lung Cancer Res*. 2022 Jul;11(7):1405-1419. doi: 10.21037/tlcr-22-465. PMID: 35958341; PMCID: PMC9359959.
7. Mauri D, Kamposioras K, Matthaïos D, Tolia M, Nixon I, Dambrosio M, Zarkavelis G, Papadimitriou K, Petricevic B, Kountourakis P, Kopecky J, Grašič Kuhar C, Popovic L, Chilingirova NP, De Mello RA, Dedić Plavetić N, Katsanos K, Mostert B, Alongi F, de Bari B, Corradini S, Kampletsas E, Gazouli I, Gkoura S, Amylidi AL, Valachis A. Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach. *Oncol Res Treat*. 2022;45(4):216-221. doi: 10.1159/000521845. Epub 2022 Jan 9. PMID: 34999585.
8. Mauri D, Kamposioras K, Tsali L, Dambrosio M, De Bari B, Hindi N, Salembier C, Nixon J, Dimitrios T, Alongi F, Hameed H, Valachis A, Papadimitriou K, Corradini S, Popovic L, Kopecky J, Rodriguez A, Antunac K, Yi J, Lovey J, Strojanc P, Saraireh H, Røtterud R, Chojnacka M, Olalla SC, Chilingirova N, De Mello RA, Amaral GA, Arbabi F, Vidra R, Rapushi E, Takeuchi D, Christopoulos C, Ivanova I, Djan I, Petricevic B, Cellini F, Mihaylova I, Plavetić ND, Kuhar CG, Takeuchi E, Kountourakis P, Ntellas P, Gazouli I, Gkoura S, Yuce S, Er Ö, Yasmina C, Kumaran G, Spahiu O, Yusuf A, Gono P, Apostolidis K, Tolia M. COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information. *Rev Recent Clin Trials*. 2022;17(1):11-14. doi: 10.2174/1574887116666211028145848. PMID: 34967300; PMCID: PMC9241076.

9. de Mello RA, Amaral GA, Neves NM, Lippo EG, Parini F, Xu S, Tolia M, Charalampakis N, Tadokoro H, Castelo-Branco P, Zhu J. Current and potential biomarkers in gastric cancer: a critical review of the literature. *Future Oncol.* 2021 Sep;17(25):3383-3396.
10. Gkantaifi A, Diamantis A, Mauri D, Nixon I, Kyriazoglou A, Baloyiannis I, Tsoukalas N, Charalampakis N, Schizas D, Cuccia F, Alongi F, de Mello RA, Iliadis G, Kamposioras K, Mazonakis M, Tolia M. Cutaneous soft tissue sarcomas: survival-related factors. *Arch Dermatol Res.* 2021 Jul 17. doi: 10.1007/s00403-021-02268-1.
11. Zhou J, Chao Y, Yao D, Ding N, Li J, Gao L, Zhang Y, Xu X, Zhou J, Halmos B, Tsoukalas N, Kataoka Y, de Mello RA, Song Y, Hu J. Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors. *Transl Lung Cancer Res* 2021 May;10(5):2148-2162.
12. Guangsheng Zhu, Dian Ren, Xi Lei, Ruifeng Shi, Shuai Zhu, Ning Zhou, Lingling Zu, Ramon Andrade De Mello, Jun Chen, Song Xu. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer. *Cancers (Basel).* 2021 Mar 19;13(6):1397 (IF = 6.126).
13. Ramon Andrade de Mello, Giovanna Araujo Amaral, Carla Chizuru Tajima, Hakaru Tadokoro, Jairo Iavelberg, Débora Simonetti, Maria Tolia, José Antonio Silva. Potential role of immunotherapy for advanced breast cancer. *Immunotherapy* 2021 Jun;13(8):633-636.
14. De Mello RA, Zhu JH, Iavelberg J, Potim AH, Simonetti D, Silva JA Jr, Castelo-Branco P, Pozza DH, Tajima CC, Tolia M, Antoniou G. Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice? *Transl Lung Cancer Res.* 2020 Dec;9(6):2311-2314 (IF = 5.132).
15. Binnie A, Fernandes E, Almeida-Lousada H, de Mello RA, Castelo-Branco P. CRISPR-based strategies in infectious disease diagnosis and therapy. *Infection.* 2021 Jan 3;1-9 (F = 3,04).
16. Kamposioras K, Mauri D, Papadimitriou K, Anthony A, Hindi N, Petricevic B, Dambrosio M, Valachis A, Kountourakis P, Kopecky J, Kuhar CG, Popovic L, Chilingirova NP, Zarkavelis G, de Mello RA, Plavetić ND, Christopoulos C, Mostert B, Goffin JR, Tzachanis D, Saraireh HH, Ma F, Pavese I, Tolia M. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth. *Front Oncol* 2020 Nov 19;10:575148. Doi: 10.3389/fonc.2020.575148. (IF = 2.53)
17. de Mello RA, Neves NM, Tadokoro H, Amaral GA, Castelo-Branco P, Zia VAA. New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. *J Clin Med* 2020 Nov 3;9(11):3543. doi: 10.3390/jcm9113543. (IF = 5.583)
18. de Mello RA, Amaral GA. Biomarkers for Non-Small Cell Lung Cancer: From the Bench to the Bedside. *J Clin Med* . 2020 Oct 21;9(10):3376. doi: 10.3390/jcm9103376. (IF = 5.583)
19. Pozza DH, De Mello RA, Araujo RLC, Velcheti V. MicroRNAs in Lung Cancer Oncogenesis and Tumor Suppression: How it Can Improve the Clinical Practice? *Curr Genomics.* 2020 Aug;21(5):372-381 (IF = 2.172).
20. De Mello RA, Neves NM, Amaral GA, Lippo EG, Castelo-Branco P, Pozza DH, Tajima CC, Antoniou G. The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer. *J Clin Med.* 2020 Jun 19;9(6):E1918. doi: 10.3390/jcm9061918 (IF = 5.583)

21. Mauri D, Kamposioras K, Tolia M, Alongi F, Tzachanis D, Petricevic B, Chilingirova N, Mihaylova I, Tsakiridis T, Salembier C, Papadimitriou K, De Mello RA et al. Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic. *Lancet Oncol*. 2020 May 13. doi: 10.1016/S1470-2045(20)30278-3. [Epub ahead of print] (IF = 35.386).
22. Mauri D, Kamposioras K, Tzachanis D, Tolia M, Valachis A, Dambrosio M, Alongi F, De Mello RA, Lövey J, Anthony A, Christopoulos C, Saraireh HH, Kountourakis P, Kampletsas E, Tsali L, Tsakiridis T, Kosovitsas I, Soukvelos A, Lymperatou D, Polyzos N, Zarkavelis G. Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel. *ESMO Open*. 2020 Apr;5(2). pii: e000696. doi: 10.1136/esmoopen-2020-000696
23. Zhu JH, De Mello RA, Yan QL, Wang JW, Chen Y, Ye QH, Wang ZJ, Tang HJ, Huang T. MiR-139-5p/SLC7A11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via PI3K/Akt signaling pathway. *Biochim Biophys Acta Mol Basis Dis*. 2020 Jun 1;1866(6):165747 (IF = 4.328)
24. De Mello RA, Lordick F, Muro K, Janjigian YY. Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. *Am Soc Clin Oncol Educ Book*. 2019 Jan; 39: 237-247.
25. Adashek JJ, Aguiar PN, Castelo-Branco P, Lopes GL Jr, de Mello RA. PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it? *Future Oncol*. 2019 May;15 (13): 1407-1410 (IF = 2.131).
26. Filho MM, Aguiar PN Jr, de Mello RA. Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. *Ann Transl Med*. 2019 Mar;7(Suppl 1): S42 (IF = 3.689).
27. Magalhães Filho M, Aguiar Junior PN, Adashek JJ, De Mello RA. How complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression?-future perspectives. *J Thorac Dis*. 2019 Mar;11(Suppl 3): S210-S211 (IF = 2.027).
28. De Mello RA, Faleiro I, Apolónio JD, Tabori U, Price AJ, Roberto VP, Castelo-Branco P. Hot topics in epigenetic regulation of cancer self-renewal for pancreatic tumors: future trends. *Future Oncol*. 2019 Mar;15 (7): 683-685 (IF = 2.131).
29. Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, De Mello RA, Dias J, Huntsman D, Hermanns T, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. *J Clin Invest*. 2019 Jan 2;129(1):223-229 (IF = 12.3).
30. De Mello RA, Castelo-Branco L, Castelo-Branco P, Pozza DH, Vermeulen L, Palacio S, Salzberg M, Lockhart AC. What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies? *Am Soc Clin Oncol Educ Book*. 2018 May 23;(38):249-261. doi: 10.1200/EDBK\_198805.
31. Aguiar P Jr, Giglio AD, Perry LA, Penny-Dimri J, Babiker H, Tadokoro H, Lopes G Jr, De Mello RA. Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access. *Immunotherapy*. 2018 Aug;10(10):887-897 (IF = 3.461).
32. De Mello RA, Aguiar PN, Tadokoro H, Farias-Vieira TM, Castelo-Branco P, de Lima Lopes G, Pozza DH. MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway. *J Thorac Dis*. 2018 Jun;10(Suppl 17):S2076-S2078. (IF = 1.804).

33. Gouvinhas C, De Mello RA, Oliveira D, Castro-Lopes JM, Castelo-Branco P, Dos Santos RS, Hespanhol V, Pozza DH. Lung cancer: a brief review of epidemiology and screening. *Future Oncol.* 2018 Mar;14(6):567-575. (IF = 2.1).
34. De Mello RA, Escriu C, Castelo-Branco P, Cabral PL, Mountzios G, Lopes GL, Madureira P. Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. *Oncotarget.* 2017 Dec 23;9(14):11805-11815 (IF = 5.138).
35. Castro D, Moreira M, Gouveia AM, Pozza DH, De Mello RA. MicroRNAs in lung cancer. *Oncotarget.* 2017 Sep 16;8(46):81679-81685 (IF = 5.138).
36. Faleiro I, Apolónio JD, Price AJ, De Mello RA, Roberto VP, Tabori U, Castelo-Branco P. The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer. *Future Oncol.* 2017 Oct;13(23):2045-2051 (IF = 2.131).
37. Aguiar PN Jr, Perry L, Penny-Dimr J, Babiker H, Tadokoro H, de Mello RA, Lopes GL Jr. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. *Ann Oncol.* 2017 Jun 15. doi: 10.1093/annonc/mdx305. [Epub ahead of print]. (Impact Factor 11.855).
38. Aguiar PN, De Mello RA, Noia Barreto CM, Perry LA, Penny-Dimri J, Tadokoro H, Lopes GL. Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. *ESMO Open* July 29, 2017, 2 (3) e000200; DOI: 10.1136/esmopen-2017-000200.
39. De Mello RA. Gastric Cancer in Southern Europe: High-Risk Disease. *Am Soc Clin Oncol Educ Book.* 2017;37:261-266. doi: 10.14694/EDBK\_175227.
40. Aguiar PN Jr, De Mello RA, Hall P, Tadokoro H, Lima Lopes G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. *Immunotherapy.* 2017 May;9(6):499-506. doi: 10.2217/imt-2016-0150 (Impact factor 2.7).
41. Jr Aguiar P, Tadokoro, H, De Mello, RA (2017). Atezolizumab for previous treated advanced non-small-cell lung cancer: should it be worthy for the clinical practice? *AME Medical Journal*, 2(3).
42. Faleiro I, Leão R, Binnie A, de Mello RA, Maia AT, Castelo-Branco P. Epigenetic therapy in urologic cancers: an update on clinical trials. *Oncotarget.* 2016, doi: 10.18632/oncotarget.14226. (Impact factor 5.008).
43. de Mello RA, de Oliveira J, Antoniou G. Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer? *Future Oncol.* 2017; 2017 Feb;13(4):295-298. PMID: 27928929 (Impact factor 2.129).
44. de Mello RA, Veloso AF, Esrom Catarina P, Nadine S, Antoniou G. Potential role of immunotherapy in advanced non-small-cell lung cancer. *Onco Targets Ther.* 2016 16; 10: 21-30 (Impact factor 2.272).
45. De-Mello RA, Pinho-Vaz C, Branca R, Campilho F, Rosales M, Roncon S, Campos-Júnior A. Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center. *Rev Assoc Med Bras (1992).* 2016; 62(7): 641 - 646 (Impact factor 0.664).

46. Aguiar P Jr, De Mello R, Tadokoro H, Santoro I, Babiker H, Avancha K, Gutierrez B, Barreto C, Lopes G. O.03: Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression. *J Thorac Oncol* 2016; 11(10S): S169-S170. doi: 10.1016/j.jtho.2016.08.006. PubMed PMID: 27676474. (Impact Factor 5.04).
47. Aguiar P Jr, Lopes G, Santoro I, Tadokoro H, Barreto C, De Mello R. PD1.02 (also presented as P2.47): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis. *J Thorac Oncol*. 2016 Oct;11(10S): S171-S172. doi: 10.1016/j.jtho.2016.08.010. PubMed PMID: 27676477. (Impact Factor 5.04).
48. Aguiar P Jr, De Mello R, Santoro I, Tadokoro H, Barreto C, Oliveira P, Lopes G. P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER: Track: Immunotherapy. *J Thorac Oncol*. 2016 Oct;11(10S):S245. doi: 10.1016/j.jtho.2016.08.115. PubMed PMID: 27676578. (Impact Factor 5.04).
49. Aguiar P Jr, De Mello R, Tadokoro H, Gutierrez B, Barreto C, Babiker H, Lopes G. P2.45: An Estimate of the Economic Impact of Treatment of NSCLC With Immunotherapy Relative to PD-L1 Expression in Brazil: Track: Immunotherapy. *J Thorac Oncol*. 2016 Oct;11(10S):S246. doi: 10.1016/j.jtho.2016.08.116. PubMed PMID: 27676579. (Impact Factor 5.04).
50. Aguiar P Jr, Lopes G, Santoro I, Tadokoro H, Barreto C, De Mello R. P2.47 (also presented as PD1.02): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis. Track: Immunotherapy. *J Thorac Oncol*. 2016 Oct;11(10S):S247-S248. doi: 10.1016/j.jtho.2016.08.118. PubMed PMID: 27676581. (Impact Factor 5.04).
51. Aguiar PN Jr, Tadokoro H, da Silva GF, Landgraf MM, Noia Barreto CM, Filardi BA, Lopes GL Jr, Oliveira P, de Mello RA. Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis. *Future Oncol*. 2016; 12 (23): 2755 - 2764. PMID: 27549331 (Impact Factor: 2.129).
52. Mello RA, Liu DJ, Aguiar PN Jr, Tadokoro H. EGFR and EML4-ALK updated therapies in non-small cell lung cancer. *Recent Pat Anticancer Drug Discov*. 2016;11(4):393-400. PMID: 27491402.
53. Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Castelo-Branco P, Mountzios G, de Mello RA. A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. *Immunotherapy*. 2016;8 (9):1011-9 (Impact Factor: 2.083).
54. De Mello RA. TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer? *Ann Transl Med*. 2016; 4 (9):185.
55. Ascierto PA, de Mello RA. Are there, or shall we discover, biomarkers to guide PD-1 inhibition? *Immunotherapy* 2016; 8(6), 681–686 (Impact factor 2.070).
56. Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Mountzios G, de Mello RA. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. *Immunotherapy*. 2016; 8 (4):479-88 (Impact factor 2.070).
57. Aguiar PN Jr, Muniz TP, Miranda RR, Tadokoro H, Forones NM, Monteiro ID, Castelo-Branco P, Janjigian YY, de Mello RA. Current advances in targeted therapies for metastatic gastric cancer: improving patient care. *Future Oncol*. 2016; 12(6): 839 - 54 (Impact factor 2.477).

58. Monteiro ID, Califano R, Mountzios G, de Mello RA. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. *Future Oncol.* 2016; 12(4): 551 - 64 (Impact factor 2.477).
59. Coelho SP, Capelas ML, Alves SM, Sá L, de Mello RA. Challenges in lung cancer approaches: from the clinical issues to the novel therapies. *Recent Adv DNA Gene Seq.* 2015; (9): 45 - 50.
60. Aguiar PN Jr, Tadokoro H, Forones NM, de Mello RA. MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer. *Immunotherapy* 2015; 7(11): 1133 - 4 (Impact factor 2.070).
61. Jr Aguiar P, Tadokoro H, Forones NM, de Mello RA. Treating operable patients with gastric cancer: Macdonald's protocol versus adjuvant chemotherapy. *Future Oncol* 2015; 11 (16): 2247 - 9 (Impact factor 2.477).
62. Califano R, Morgillo F, de Mello RA, Mountzios G. Role of MET amplification on resistance to anti-EGFR agents for non-small cell lung cancer. *Ann Transl Med* 2015; 3 (6): 81.
63. Madureira P, de Mello RA, de Vasconcelos A, Zhang Y. Immunotherapy for Lung Cancer: For whom the bell tolls? *Tumor Biology* 2015; 36 (3): 1411 - 22 (Impact factor 3.611).
64. De Mello RA, Pousa I, Pereira D. Nivolumab for advanced squamous cell lung cancer: what are the next steps? *Lancet Oncol* 2015; 16 (3): 257 - 71. (Impact factor 24.229).
65. Monteiro IdeP, Madureira P, de Vasconcelos A, Pozza DH, de Mello RA. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. *Pharmacogenomics* 2015; 16 (3): 257 - 71 (Impact factor 3.97).
66. Domingues D, Turner A, Silva MD, Marques DS, Melindez JC, Wannesson L, Mountzios G, de Mello RA. Immunotherapy and lung cancer: current developments and novel targeted therapies. *Immunotherapy* 2014; 6 (11): 1221 - 35 (Impact factor = 2.44).
67. Gonçalves R, Lopes A, Júlio C, Durão C, de Mello RA. Rare Tumor 2014; 6 (4): 5588. Doi: 10.4081/rt.2014.5588.
68. de Mello RA. Genetic polymorphisms and non-small-cell lung cancer: future paradigms. *Einstein (Sao Paulo)* 2014; 12 (4): 524 - 526.
69. Marques AM, Turner A, de Mello RA. Personalizing medicine for metastatic colorectal cancer: current developments. *World J Gastroenterol* 2014; 20 (30): 10425-31 (Impact factor = 2.5).
70. de Mello RA, Alves MP, Gerós S, Moreira F, Azevedo I, Dinis J. Cetuximab plus platinum-based chemotherapy in Head and Neck Cancer: a retrospective study in a single European Institution. *PLOS ONE* 2014; 9 (2): e86697. DOI: 10.1371/journal.pone.0086697 (Impact factor 4.02).
71. Madureira P, de Mello RA. BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy. *Mol Diagn Ther* 2014; 18 (3): 285-91. DOI: 10.1007/s40291-013-0081-0 (Impact factor 2.589).
72. Marques I, Araújo A, de Mello RA. Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. *World J Gastroenterol* 2013; 19 (44): 7955 - 71 (Impact factor = 2.5).

73. De Mello RA, Madureita P, Carvalho LS, Araújo A, O'Brien M, Popat S. EGFR mutation and advanced non-small-cell lung cancer: Current developments and personalized therapies'. *Pharmacogenomics* 2013; 14 (14): 1765-77. (Impact factor = 3.97).
74. Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araújo A, de Mello RA. Personalizing therapies in advanced gastric cancer – molecular mechanisms, current biomarkers and novel anti-HER2 therapies. *World J Gastroenterol* 2013; 19 (18): 6383 – 6397. (Impact factor = 2.5).
75. De Mello RA, Marques AM, Araújo A. Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies. *World J Gastroenterol* 2013; 19 (38): 6315 – 6318. (Impact factor = 2.5).
76. De Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: a step forward. *World J Gastroenterol* 2013; 19 (37): 6165-6169 (Impact factor = 2.5).
77. De Mello RA, Ferreira M, Soares-Pires F, Costa S, Cunha J, Oliveira P, Hespanhol V, Reis RM. The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 loci on the risk and prognosis of Portuguese patients with non-small cell lung cancer. *PLoS ONE* 2013; 8 (9): e72373. DOI: 10.1371/journal.pone.0072373. (Impact factor = 4.05).
78. De Mello RA, Araújo A. Anaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalizing therapy. *CLINICS (Sao Paulo)* 2013; 68 (5): 726. (Impact factor = 2.058).
79. Araújo A, de Mello R, Coelho A. Editorial: Terapêutica Personalizada do Cancro do Pulmão. *Revista Grupo Estudos Cancro Pulmão* 2013; 10 (1): 9 – 12. ISSN 1645-9466. Web site: <http://www.gecp.pt/revista/arquivo/item/revistas-2013>
80. De Mello RA, Araujo A, Hespanhol V, Reis RM. Loci identified through Genome Wide Association Study and risk of lung cancer: is there anything more? *São Paulo Med J* 2013; 131 (2): 135 – 6. (Impact factor = 0.723).
81. De Mello RA, Araújo A. Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices. *CLINICS (Sao Paulo)* 2012; 67 (11): 1349. (Impact factor = 2.058).
82. de Mello RA. EGF+61 A>G Polymorphisms and Lung Cancer Risk: Future Directions. *J Pulmonar Respirat Med* 2012; S5: e001. DOI: 10.4172/2161-105X.S5-e001. <http://www.omicsonline.org/ArchiveJPRM/articleinpressJPRM.php>
83. de Mello RA, Pires FS, Marques DS, Oliveira J, Rodrigues A, Soares M, Azevedo I, Peixoto A, Santos C, Pinto C, Hespanhol V, Teixeira MR, Amaro T, Queiroga H, Araújo A. EGFR exons mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. *Tumour Biol* 2012; 33 (6): 2061 – 8. DOI: 10.1007/s13277-012-0465-5. (Impact Factor = 3.611).
84. De Mello RA. Back to EGF+61 polymorphisms and Lung Cancer Risk: future perspectives. *São Paulo Med J*. 2012; 130 (6): 415-16. (Impact Factor = 0.723)
85. de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J, Oliveira P, Hespanhol V, Reis RM. Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a

Portuguese population: a case-control study. *Tumour Biol* 2012; 36 (5): 1341 – 8. DOI: 10.1007/s13277-012-0382-7 (Impact Factor = 3.611).

86. de Oliveira MG, Piazza T, Gaião L, Ramalho LMP, Pozza DH, de Mello RA. Retinoblastoma and p53 protein expression in pre-malignant oral lesions and oral squamous cell carcinoma. *Mol Med Report* 2012; 6 (1): 163 – 166. (IF = 0.307). DOI: 10.3892/mmr.2012.876. (Impact factor =0.418).
87. Araújo A, Coelho A, de Mello RA, Azevedo I, Soares M, Queiroga H, Teixeira E, Parente B, Barata F. Personalizing medicine - strategies for implementing the evaluation of ALK rearrangement in non-small-cell lung cancer in Portugal. *Rev Port Pneumol* 2012; 18 (5): 244-46. DOI 10.1016/j.rppneu.2012.04.011 (Impact factor = 0.226).
88. De Mello RA. Metastatic Melanoma and vemurafenib: novel approaches. *Rare Tumors* 2012; 4 (2): e31. DOI: 10.4081/rt.2012.e31.
89. De Mello RA. Sacrum osteosarcoma after pelvic irradiation for uterine cervical cancer: highlight issues. *São Paulo Med J.* 2012; 130 (5): 344 – 345. (Impact Factor = 0.711).
90. De Mello RA, Magalhães MA, Villas-Boas A. Stridor and respiratory failure due to tracheobronchomalacia: a case report and review of the literature. *São Paulo Med J.* 2012; 130 (1): 61 – 4 (Impact Factor = 0.711).
91. De Mello RA, de Vasconcelos A, Ribeiro RA, Pousa I, Afonso N, Pereira D, Rodrigues H. Insights into p95 Her2 and breast cancer: molecular pathways and targeted therapies. *Recent Pat DNA Gene Seq.* 2012; 6 (1): 56 - 63. (SCI = 0.83).
92. De Mello RA, Costa BM, Reis RM, Hespanol V. Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes and targeted therapies. *Recent Patents on Anti-Cancer Drug Discovery.* 2012; 7 (1): 118 – 31. (Impact Factor = 4.299).
93. de Mello RA, Marques DS, Medeiros R, Araujo AM. Epidermal growth factor receptor and K-Ras in non-small cell lung cancer -molecular pathways involved and targeted therapies. *World J Clin Oncol* 2011; 2 (11): 367-376.
94. De Mello RA, Gregório T, Cardoso T. Chylous ascites due to signet ring cell gastric adenocarcinoma. *Niger J ClinPract.* 2012; 15 (4): 487 - 90. (Impact Factor = 0.192).
95. de Mello RA, Santos DS, Freitas-Silva MP, Andrade JA. Renal failure due to primary amyloidosis: a case report and literature review. *São Paulo Med J.* 2011; 129 (3):176-80. (Impact factor = 0.577).
96. De Mello RA, Figueiredo P, Marques M, Sousa G, Carvalho T, Gervasio H. Concurrent breast stroma sarcoma and breast carcinoma: a case report. *J Med Case Rep* 2010, 4(1):414. (Highly accessed). DOI: 10.1186/1752-1947-4-414.
97. De Mello RA, Fonseca E, Brochado M, Quinaz JM. Hemophagocytic Syndrome Associated with Hodgkin's Lymphoma First Presenting as Fever and Pancytopenia *Case Rep Med* 2010, 2010. DOI: 10.1155/2010/759651.
98. De Mello RA, Ferreira D, Dias da Costa JM, Rosas MJ, Quinaz JM. Multiple-System Atrophy with Cerebellar Predominance Presenting as Respiratory Insufficiency and Vocal Cords Paralysis. *Case Rep Med* 2010, 2010. DOI: 10.1155/2010/351239.

99. González R, Leyva A, Melo RAB, Moreira R, Pessoa C, Farias R, Moraes M: Método para estudo in vivo da angiogênese: indução de neovascularização na córnea de coelho. *Acta Cir Bras* 2000, 15 (3):168-173. (Impact factor = 0.584)

## Recent Meeting Abstracts Publications in International Science Indexed Journals\*

1. Roque K, Otoyá I, Valdivieso N, Morante Z, Fuentes H, Neciosup S, Gomez HL, Cotito J, Ziegler G, Peña E, Vidaurre T, De Mello RA, Castañeda C, Between Hormone Receptors and Her2 status in breast cancer patients relapse P05-06-05, Santo Antonio Breast Cancer Symposium (SABCS), Santo Antonio, TX, USA, 5-9 December 2023
2. Bighetti B, Neto JT, Pereira R, Souza LC, Santoro IL, Tadokoro H, Ribas C, De Mello RA. Efficacy and tolerability of weekly 40mg/m<sup>2</sup> cisplatin radiosensitizing modified regimen for locally-advanced head and neck squamous cell carcinoma radical treatment with chemoradiotherapy: A university hospital experience. *J Clin Oncol* 38: 2020 (suppl; abstr e18512), (IF = 28.245).
3. De Mello RA, Ayoub E, Castelo-Branco P, Zia V, Savio A, Pozza DH, Tadokoro H, Teich N. Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitinib for advanced renal cell carcinoma in the U.K. Perspective. *Journal of Clinical Oncology* 38, no. 6\_suppl (February 20, 2020) 689-689 (IF = 28.245).
4. De Mello RA, Aguiar PN, Haaland B, Tan PS, Fernandes MT, Spinosa ACB, Del Giglio A, Lopes G; Assessing treatment benefits with CDK4/6i+ET for hormone receptor-positive advanced breast cancer: A network meta-analysis. *J Clin Oncol* 37, 2019 (suppl; abstr e12543) (IF = 28.245).
5. Aguiar PN, De Mello RA, Tadokoro H, Lopes G. Economic impact of immune checkpoint inhibitor therapy in Brazil and strategies to improve access. *J Clin Oncol* 35, 2017 (suppl; abstr 6612) (IF = 28.245).
6. Jr Aguiar PN, Tadokoro H, Noia-Barreto CM, Santoro IL, de Mello RA, Babiker HM, Lopes G. Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. *J Clin Oncol (Meeting Abstracts)* May 2016 vol. 34 no. 15\_suppl 9033. (Impact Factor = 18.970).
7. Coelho SP, Costa T, Barbosa MM, Capelas ML, de Mello RA, Sá L. Palliative Home Care, for a Holistic Approach to the Patient and Family. *Palliative Med* 2016, Abstract PO101. DOI: 10.1177/0269216316646056.
8. Coelho SP, Costa T, Barbosa MM, Capelas ML, de Mello RA, Sá L. *Palliative Med* 2016, Abstract PO100. DOI: 10.1177/0269216316646056.
9. De Mello RA, Oliveira MVGB, Oliveira JS, Oliveira FM, Bastos JF. 5-fluorouracil-leucovorin chemoradiotherapy to the adjuvant treatment of operable gastric cancer: A retrospective data from a Brazilian reference cancer institution. *J Clin Oncol* 2016; 34 (suppl): e15540 (Impact Factor = 18.970).
10. Aguiar Jr PN, Tadokoro H, Noia-Barreto C, Santoro IL, de Mello RA, Babiker H, Avancha K, Lopes GL. abstr 9033 Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. *J Clin Oncol* 2016; 34 (Suppl): abstr 9033 (Impact Factor = 18.970).

11. Coelho SP, Capelas ML, Alves S, Alves N, Sa L, De Mello, RA. Optimizing home-based palliative care as a good practice to meet patient´s and families' needs. Eur J Cancer 2015; 51(Suppl3): S210 (meeting abstract 1519) – (impact factor = 5.417).
12. Castelo-Branco P, Leao R, De Mello RA, Lipman T, Campbell B; Price A, Zhang C; Buerno S, Gomes A, Bristow RG, Schweiger M, Hamilton R, Zlotta A, Figueiredo A, Klocker H, Sueltmann H, Tabor iU. Hypermethylation of a specific area in theTERTpromoter defines a novel risk stratification biomarker for prostate cancer patients submitted to radical prostatectomy. Eur J Cancer 2015; 51 (Suppl 3): S474 (meeting abstract 2503) – (impact factor = 5.417).
13. Aguiar P., Santoro I, Tadokoro H, Filardi BA, Lopes GL; Picon FS, Barreto CMN, Muniz PC, Borges AM, Oliveira P, Mountzios G, Riera R, De Mello RA. Definitive chemoradiotherapy for loco-regionally advanced squamous cell head and neck cancer: Is cisplatin more effective than carboplatin? - a systematic review and meta-analysis. Eur J Cancer 2015; 51 (Suppl 3): S566 – S567 (meeting abstract 2826) – (impact factor = 5.417).
14. Aguiar P., Santoro I, Tadokoro H, Filardi BA, Lopes GL; Picon FS, Barreto CMN, Muniz PC, Borges AM, Oliveira P, Mountzios G, Riera R, De Mello RA. The role of PD-L1 expression as a predictive biomarker in advanced non-small cell lung cancer: A network meta-analysis. Eur J Cancer 2015; 51 (Suppl 3): S644 (meeting abstract 3122) – (impact factor = 5.417).
15. Aguiar P., Santoro I, Tadokoro H, Filardi BA, Lopes GL; Picon FS, Barreto CMN, Muniz PC, Borges AM, Oliveira P, Mountzios G, Riera R, De Mello RA. Polled analysis of nivolumab for the treatment of advanced non-small cell lung cancer and the role of PD-L1 as a biomarker. Eur J Cancer 2015; 51 (Suppl 3): S624 (meeting abstract 3080) – (impact factor = 5.417).
16. Correia JL, Coelho SP, Capelas ML, Alves P, Sá L, de Mello RA. Palliative sedation in terminal cancer patients with refractory uncontrolled symptoms. J Clin Oncol 2015; 33 (15\_suppl): e20551 (Impact Factor = 18.970).

## Selected Congresses and Conferences

1. Brazilian Congress of Cancerology, CONCAN 2023, Salvador, Brasil, 27-29 July 2023
2. ASCO 2023 annual meeting, 2 – 6 June 2023, McCormick Place, Chicago, USA
3. XIV Congresso Internacional de Uro-oncologia | IX Simpósio Multiprofissional de Uro-oncologia, 12th to 15<sup>th</sup> April 2023, São Paulo, Brasil
4. III UNIONCO – United International Oncology Congress, 1<sup>st</sup> and 2<sup>nd</sup> December 2022, São Paulo, Brazil
5. ASCO 2022 annual virtual meeting, 4 – 7 June 2022, Chicago, USA
6. II UNIONCO – United International Oncology Congress, 5<sup>th</sup> December 2021, São Paulo, Brazil
7. ASCO 2021 annual virtual meeting, 4 – 8 June 2021, Chicago, USA
8. SBOC 2021 – Brazilian Congress of Clinical Oncology, 17 – 20 November 2021, Salvador, BA, Brazil

9. I UNIONCO – United International Oncology Congress, 3<sup>th</sup> December 2020, São Paulo, Brazil
10. XXII CONCAN – Brazilian Congress of Cancerology, 25 – 26 September 2020, São Paulo, SP, Brazil
11. ASCO 2020 annual virtual meeting, 20 – 31 May 2020, Chicago, USA
12. XXI Brazilian Congress of Clinical Oncology (SBOC2019), Rio de Janeiro, Brazil, 23-26 October 2019.
13. 1st Southeastern European Immunotherapy (SEIC2019), Zagreb, Croatia, 11-12 October 2019.
14. 2019 American Society of Clinical Oncology (ASCO) annual meeting. Chicago, 31st May 2019 to 3rd June 2019.
15. ONCONET SUDOE. EUROPEAN NETWORK OF TRANSLATIONAL RESEARCH AND INNOVATION IN ONCOLOGY. Navarrabiomed 16th and 17th May 2019 - Molecular Biology, Cancer and Bioinformatics, Pamplona, Spain.
16. THE INTERNATIONAL GASTRIC CANCER CONGRESS IGCC 2019, Prague, 9 – 11th May 2019.
17. 2019 ACP Internal Medicine Meeting, Philadelphia, 11 – 13 April 2019
18. ESMO World Gastrointestinal Cancer Conference, Barcelona, 20 – 23 June 2018
19. 2018 ASCO annual meeting, McConick Place, Chicago, 1 – 5 June 2018
20. 2018 ACP Internal Medicine Meeting New Orleans, USA, 16th-19th April 2018
21. I Brazilian Oncology Week – Brazilian Congress of Surgical Oncology and Brazilian Congress of Clinical Oncology (SBOC 2017), Rio de Janeiro, Brazil, 25 to 28 October 2017.
22. Annual ESMO (European Society for Medical Oncology) Congress. Copenhagen, Denmark - 07 Oct - 11 Oct 2016
23. Brazilian Congress of Clinical Oncology (SBOC 2015), Foz do Iguaçu, PR, Brazil, 29 October - 1 November 2015.
24. 18th ECCO - 40th ESMO European Cancer Congress, 25 - 29 September 2015. Vienna, Austria.
25. 5th European Lung Cancer Conference ELCC - ESMO and IALSC, 15 - 18 April, 2015, Geneva, Switzerland.

## Selected Conference Presentations

1. Tajima CC, Bittencourt A, E. Marques, E. Nóbrega, De Mello RA. The role of 18F-FDG with specific breast protocol as prognostic biomarker of invasive breast carcinoma. Poster presentation at ESMO Virtual Congress 2020, Science Weekend, 19 – 21 September 2020. (POSTER PRESENTATION).
2. De Mello RA, Ayoub E, Castelo-Branco P, Zia V, Savio A, Pozza DH, Tadokoro H, Teich N. Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitinib for advanced renal cell carcinoma in the U.K. Perspective. ASCO GU, 14th Feb 2020, San Francisco, USA. (POSTER PRESENTATION).
3. Santos M, Ayoub E, Bigheti B, Pereira R, Souza V, Almeida M, Tadokoro H, Ribas C, Pádua T, de Mello RA, Gil J, Forones N. A retrospective study of ageing patients with gastrointestinal cancer treated between 2014 – 2018. Brazilian Oncology Week – Brazilian Congress of Surgical Oncology and Brazilian Congress of Clinical Oncology (SBOC 2019), Rio de Janeiro, Brazil, 25 to 28 October 2019. (ABSTRACT).
4. Parini F, Silva EC, Sávio AL, Rodrigues JC, de Mello RA. Geriatric kidney cancer patient treated with checkmate 214 protocol. II FOB-USP medical meeting. 7 to 9 November 2019, Bauru, São Paulo, Brazil. (Poster presentation).
5. Silva EC, de Mello RA, Gatti R, Rogrigues JC. Nive-years follow up of cutaneous lymphoma in geriatric patient – A case report. II FOB-USP medical meeting. 7 to 9 November 2019, Bauru, São Paulo, Brazil. (Poster presentation).
6. De Mello RA, Ayoub E, Castelo-Branco P, Antunes MB, Parini F, Pozza DH, Tadokoro H. THE ROLE OF PRECISION MEDICINE IN THE OPTIMIZATION OF THE SYSTEMIC TREATMENT FOR ADVANCED NEOPLASMS presented at XXI Brazilian Congress of Clinical Oncology (SBOC2019), Rio de Janeiro, Brazil, 23-26 October 2019 (POSTER PRESENTATION)
7. De Mello RA, Faleiro I, Apolónio JD, Tabori U, Price AJ, Roberto VP, Castelo-Branco P. Epigenetic regulation of cancer self-renewal differs between pancreatic and thyroid tumors. Brazilian Oncology Week – Brazilian Congress of Surgical Oncology and Brazilian Congress of Clinical Oncology (SBOC 2017), Rio de Janeiro, Brazil, 25 to 28 October 2017. (ORAL PRESENTATION).
8. De Mello RA, Aguiar Jr. P, Cabral P, Chaves F, Liu D, Soares JP, Mountzios G, Tadokoro H, Lopes GL. P3.02b-081 Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis. IASLC WCLC 2016 | 17th World Conference on Lung Cancer. December 4 – 7, 2016, Vienna, Austria. (POSTER PRESENTATION).
9. Aguiar Jr PN, de Mello R, Tadokoro H, Babiker H.M., Lopes Jr G. 1224P - Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression. Annual ESMO (European Society for Medical Oncology) Congress. Copenhagen, Denmark - 07 Oct - 11 Oct 2016. (POSTER PRESENTATION).
10. Aguiar P Jr, De Mello R, Tadokoro H, Santoro I, Babiker H, Avancha K, Gutierrez B, Barreto C, Lopes G. O.03: Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression. The 7th Latin American Conference on Lung Cancer was held in August 25 – 27, 2016 in Panama City, Panama. (POSTER PRESENTATION).
11. Aguiar P Jr, Lopes G, Santoro I, Tadokoro H, Barreto C, De Mello R. PD1.02 (also presented as P2.47): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis. The 7th Latin American Conference on Lung Cancer was held in August 25 – 27, 2016 in Panama City, Panama. (POSTER PRESENTATION).

12. Aguiar P Jr, De Mello R, Santoro I, Tadokoro H, Barreto C, Oliveira P, Lopes G. P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER: Track: Immunotherapy. The 7th Latin American Conference on Lung Cancer was held in August 25 – 27, 2016 in Panama City, Panama. (POSTER PRESENTATION).
13. Aguiar P Jr, De Mello R, Tadokoro H, Gutierrez B, Barreto C, Babiker H, Lopes G. P2.45: An Estimate of the Economic Impact of Treatment of NSCLC With Immunotherapy Relative to PD-L1 Expression in Brazil: Track: Immunotherapy The 7th Latin American Conference on Lung Cancer was held in August 25 – 27, 2016 in Panama City, Panama. (ORAL PRESENTATION).
14. Aguiar P Jr, Lopes G, Santoro I, Tadokoro H, Barreto C, De Mello R. P2.47 (also presented as PD1.02): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis. The 7th Latin American Conference on Lung Cancer was held in August 25 – 27, 2016 in Panama City, Panama. (POSTER PRESENTATION).
15. Aguiar Jr PN, Tadokoro H, Noia-Barreto C, Santoro IL, de Mello RA, Babiker H, Avancha K, Lopes GL. abstr 9033 Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. ASCO annual meeting 2016, Chicago, USA, 3 – 7, June 2016 (POSTER PRESENTATION).
16. Coelho SP, Capelas ML, Sá L, de Mello RA. Expectation from the oncological palliative patient regarding the end-of-life: an integrative review. Brazilian Congress of Clinical Oncology (SBOC 2015), Foz do Iguaçu, PR, Brazil, 29 October to 1 November 2015 (POSTER PRESENTATION).
17. Castelo-Branco P, Leão R, de Mello RA, Lipman T, Campbell B, Price A, Zhang C, Buerno S, Gomes A, Bristow RG, Schweiger M, Hamilton R, Zlotta A, Figueiredo A, Klocker H, Sueltmann H, Tabori U. Hypermethylation of a specific area in the TERT promoter defines a novel risk stratification biomarker for prostate cancer patients submitted to radical prostatectomy. 18th ECCO - 40th ESMO European Cancer Congress - Proffered paper session on "Genitourinary Malignancies - Prostate Cancer" on 26 September 2015 (ORAL PRESENTATION).
18. Aguiar Jr P, Santoro I, Tadokoro H, Filardi BA, Lopes GL, Picon FS, Noia-Barreto CM, Muniz PC, Borges AM, Oliveira P, Mountzios G, Riera R, de Mello RA. Definitive chemoradiotherapy for loco-regionally advanced squamous cell head and neck cancer: is cisplatin more effective than carboplatin? – a systematic review and meta-analysis. 18th ECCO - 40th ESMO European Cancer Congress. Poster Session: "Head and Neck" on 27 September 2015. (POSTER PRESENTATION).
19. Aguiar Jr P, Santoro I, Tadokoro H, Filardi BA, Lopes GL, Picon FS, Noia-Barreto CM, Muniz PC, Borges AM, Oliveira P, Mountzios G, Riera R, de Mello RA. The role of PD-L1 expression as a predictive biomarker in advanced non-small cell lung cancer: A network meta-analysis. 18th ECCO - 40th ESMO European Cancer Congress. Poster Session: "Lung Cancer - Metastatic Disease" on 27 September 2015. (POSTER PRESENTATION).
20. Aguiar Jr P, Santoro I, Tadokoro H, Filardi BA, Lopes GL, Picon FS, Noia-Barreto CM, Muniz PC, Borges AM, Oliveira P, Mountzios G, Riera R, de Mello RA. Polled analysis of nivolumab for the treatment of advanced non-small cell lung cancer and the role of PD-L1 as a biomarker. 18th ECCO - 40th ESMO European Cancer Congress. Poster Session: "Lung Cancer - Metastatic Disease" on 27 September 2015. (POSTER PRESENTATION).
21. Coelho SP, Capelas ML, Alves S, Alves N, Sá L, de Mello RA. Optimizing home-based palliative care as a good practice to meet patients and families' needs. 18th ECCO - 40th ESMO European Cancer Congress. Poster Session: "Supportive Care and Palliation" on 27 September 2015. (POSTER PRESENTATION).
22. Coelho SP, Capelas ML, Sá L, Costa T, Pinho-Reis C, de Mello RA. Morte e “o morrer” com dignidade: cuidados paliativos no domicílio. Jornadas de Investigação da Associação Portuguesa de Cuidados Paliativos, Escola Superior de Saúde Dr. Lopes Dias, em Castelo Branco, Portugal, 20 e 21 Março de 2015. (POSTER PRESENTATION).

23. Costa T, Capelas ML, Coelho P, de Mello RA. Estratégias adotadas pelo cuidador informal de uma pessoa idosa em fim de vida: uma análise do contexto da prática. I Jornadas de Investigação da Associação Portuguesa de Cuidados Paliativos, Escola Superior de Saúde Dr. Lopes Dias, em Castelo Branco, Portugal, 20 e 21 Março de 2015. (POSTER PRESENTATION).
24. Coelho SP, Capelas ML, Sá L, Costa T, Pinho-Reis C, de Mello RA. Morte e o Morrer com dignidade: cuidados paliativos no domicílio, I Jornadas de Investigação da Associação Portuguesa de Cuidados Paliativos, 20 e 21 de Março de 2015, Castelo Branco, Portugal. (POSTER PRESENTATION).
25. Costa T, Capelas ML, Soelho P, de Mello RA. Estratégias adotadas pelo cuidados informal de uma pessoa idosa em fim de vida: uma análise do contexto da prática. I Jornadas de Investigação da Associação Portuguesa de Cuidados Paliativos, 20 e 21 de Março de 2015, Castelo Branco, Portugal. (POSTER PRESENTATION).
26. Coelho SP, Afonso D, de Mello RA, Araújo H, Barbas A, Rodrigues D, Silva C, Silva V, Vilhena A. Sedación en cuidados paliativos: una revisión integradora (Paper number 233). X Congreso Nacional de la Sociedad Española de Cuidados Paliativos. Centro de Convenciones Norte (IFEMA) de Madrid, 3 - 15 November 2014 (POSTER PRESENTATION).
27. Coelho SP, Capelas ML, Ferreira C, Alvarenga M, de Mello RA, Sá L. Morir en casa para fin de vida con calidad: una revisión integral (Paper number 149). X Congreso Nacional de la Sociedad Española de Cuidados Paliativos. Centro de Convenciones Norte (IFEMA) de Madrid, 3 - 15 November 2014 (POSTER PRESENTATION).
28. Coelho SP, Capelas ML, Silva R, de Mello RA, Costa T, Reis C, Sá L. Cuidados paliativos en el domicilio: revisión de la producción científica (Paper number 116). X Congreso Nacional de la Sociedad Española de Cuidados Paliativos. Centro de Convenciones Norte (IFEMA) de Madrid, 3 - 15 November 2014 (POSTER PRESENTATION).
29. Coelho SP, Capelas ML, Reis C, de Mello RA, Silva R. Estado cognitivo de los pacientes con necesidades paliativas en las unidades de hospitalización (Paper number 115). X Congreso Nacional de la Sociedad Española de Cuidados Paliativos. Centro de Convenciones Norte (IFEMA) de Madrid, 3 - 15 November 2014 (POSTER PRESENTATION).
30. De Mello RA, Pantarotto-Alves M, Gerós S, Moreira F, Vieira C, Azevedo I, Dinis J. Cetuximab plus platinum-based chemotherapy in head and neck cancer: a retrospective study in a single European Institution. European Cancer Congress 2013 - 17th ECCO, 38th ESMO, 32th ESTRO, Amsterdam, 28 September - 1 October 2013. POSTER PRESENTATION.
31. De Mello RA, Ferreira M, Soares-Pires F, Costa S, Cunha J, Oliveira P, Hespanhol V, Reis RM. The role of polymorphic variants on vascular endothelial growth factor gene and non-small cell lung cancer: a Portuguese prospective study. European Cancer Congress 2013 - 17th ECCO, 38th ESMO, 32th ESTRO, Amsterdam, 28 September to 1 October 2013. POSTER PRESENTATION.
32. de Mello RA, Ferreira C, Pereira D, Espírito-Santo A, Moreira I, Oliveira I, Viterbo L, Marques M, Henrique R, Oliveira A, Martins G, Martins A, Dominguez N, Mariz JM. Síndrome de Richter: caracterização clínica e citogenética de 6 casos ocorridos entre Março e Maio 2012. Portuguese Society of Hematology Annual Meeting. Hotel Porto Palácio. From 8 - 10 November 2012. Porto, Portugal. POSTER PRESENTATION.
33. de Mello RA, Ferreira M, Pires FS, Costa S, Luis M, Pozza DH, Cunha J, Oliveira P, Hespanhol V, Reis RM. The role of genetic polymorphisms at the chromosomes 5p15.33, 6p12, 6p21, 6p21.3 and 5q25 into non-small cell lung cancer prognosis: a Portuguese prospective study. Brazilian Congress of Cancer (CONCAN 2012). Sponsored by Brazilian Society of Cancer (SBC). Centro de Eventos. Fortaleza, 24 - 27 October, 2012. Brazil. ORAL PRESENTATION.

34. de Mello RA, Leça L, Raimundo A, Ferreira P. Porocarcinoma écrino: 10 anos de experiência do Instituto Português de Oncologia (IPO) do Porto, Portugal. Brazilian Congress of Cancer (CONCAN 2012). Sponsored by Brazilian Society of Cancer (SBC). Centro de Eventos. Fortaleza, 24 - 27 October, 2012. Brazil. POSTER PRESENTATION.
35. Fonte DP, Trigo ML, de Mello RA, Carvalho, LG, Vendeira LA, Pinto MG. Quando a braquiterapia da próstata não parece ser suficiente: relato de um caso clínico e discussão. Brazilian Congress of Cancer (CONCAN 2012). Sponsored by Brazilian Society of Cancer (SBC). Centro de Eventos. Fortaleza, 24 - 27 October, 2012. Brazil. POSTER PRESENTATION.
36. De Mello RA, Rosinha A, Sousa N, Faustino C, Begonha R, Maurício J. Adenocarcinoma da próstata versus prostatite granulomatosa responsiva à terapia hormonal: um desafio clínico. Spring Meeting Oncology 2012. Évora, 19 - 22 April 2012, Portugal. POSTER PRESENTATION.
37. Rosinha A, De Mello RA, Carneiro F, Faustino C, Sousa N, Begonha R, Maurício J. Carcinoma de células renais metastizado (MRCC): um caso de sucesso/uma sobrevivência pouco habitual. Spring Meeting Oncology 2012. Évora, 19 to 22 April 2012, Portugal. POSTER PRESENTATION.
38. De Mello RA, Marques DS, Bordalo-Sá J, Medeiros R, Pereira D. O papel do polimorfismo genético da Interleucina 10 -592 C/A na recidiva ganglionar e localizada no carcinoma epitelial do ovário: um novo marcador? Oncology National Congress. Portuguese Society of Oncology. Albufeira, 11 - 15 November, 2011. Portugal. ORAL PRESENTATION.
39. Alves MP, Mello RA, Lucena I, Couto R, Afonso N. A tomografia de emissão de positrões (PET/CT) no cancro da mama - seis anos de experiência do IPO do Porto. Oncology National Congress. Portuguese Society of Oncology. Albufeira, 11 - 15 November, 2011. Portugal. ORAL PRESENTATION.
40. De Mello RA, Ferreira M, Costa BM Pires F, Neves I, Duarte N, Figueiredo F, Guimarães JT, Hespanhol V, Reis RM. Association Between +61 A/G Polymorphism in the EGF Gene and Non-Small Cell Lung Cancer Risk in Male Caucasians. Abstract 9139 (poster presentation) at 16 European Multidisciplinary cancer congresses /36 ESMO/30 ESTRO. 23-27 September, 2011. Stockholm, Sweden. POSTER PRESENTATION.
41. Bordalo-Sá J, de Mello RA, Marques DS et al. O Papel prognóstico e preditivo do polimorfismo da IL-8 T-251A no Carcinoma epitelial do ovário (P29). Jornadas de Oncologia do IPOPORTO, Espinho (Portugal), 7 July 2011. POSTER PRESENTATION.
42. De Mello RA, Pires F, Neves I, Teixeira ND, Figueiredo F, Magalhães A, Mores A, Barbosa A, Araújo I, Queiroga H, Hespanhol V. Avaliação dos factores de impacto no comportamento tumoral e sobrevivência global do Carcinoma do Pulmão Não Pequenas Células em estadio avançado. Évora Oncology Spring Meeting 2011. Évora Hotel, from March 31 to April 2, 2011. Évora, Portugal. POSTER PRESENTATION.
43. De Mello RA, de Oliveira MG, Piazza T, Gaião L, Ramalho LM, Pozza DH. Retinoblastoma and p53 protein expression in pre-malignant oral lesions and oral squamous cell carcinoma. First prize, poster category. Évora Oncology Spring Meeting 2011. Évora Hotel, from March 31 to April 2, 2011. Évora, Portugal. POSTER PRESENTATION.
44. De Mello RA, Fonseca E, Brochado M, Quinaz JM. Síndrome Hemofagocítica associada a Linfoma de Hodgkin. I Jornadas do Serviço de Medicina Interna e III Jornadas de Infeciologia do Hospital Central do Funchal. Madeira Island, Portugal. 26 - 30 October 2010. POSTER PRESENTATION.
45. De Mello RA, Gregório T. Chylous Ascites as clinical presenting of Gastric Adenocarcinoma. Jornadas de Oncologia do IPOPORTO. Hotel Sol Verde, Espinho, Porto, July 9 2010. Portugal. POSTER PRESENTATION.

46. De Mello RA, Castro P, Marques DS, Pantarotto M, Moreira G, Azevedo E, Cardoso T. Association between Body Iron Stores with Ischemic Stroke Prognosis and Dependent Status. XXVII Reunión de la Sociedad Gallega de Medicina Interna. Santiago de Compostela, 25 - 26 June 2010. Spain. POSTER PRESENTATION.
47. De Mello RA, Ferreira D, Dias da Costa M, Rosas MJ, QuinazJM. Respiratory Failure and Vocal Cords Paralysis due to Atrophy of the cerebellar predominance of Multiple Systems (MSA-c): A Case Report. XXVII Reunión de la Sociedad Gallega de Medicina Interna. Santiago de Compostela, 25 - 26 June 2010. Spain. POSTER PRESENTATION.
48. De Mello RA, Freitas-Silva M, Andrade JÁ. Primary Amyloidosis and Renal Failure: Case Report. XXVII Reunión de la Sociedad Gallega de Medicina Interna. Santiago de Compostela, 25 - 26 June 2010.Spain. POSTER PRESENTATION.
49. Gregório T, de Mello RA. Quiloperitoneo em paciente com adenocarcinoma gástrico de células em anel de sinete: Relato de caso. 16º Congresso Nacional Medicina Interna. May 26-29, 2010, Vilamoura, Portugal. POSTER PRESENTATION.
50. De Mello RA, Pais A, Carvalho T, Gervásio H. Leucemia Mielóide Aguda secundária numa doente com carcinoma inflamatório da mama. VII Congresso Nacional de Senologia da Sociedade Portuguesa de Senologia. Vilamoura, 15 November, 2009. Portugal. POSTER PRESENTATION.
51. De Mello RA, Mendes A, castro P, Castro S, Moreira G, Azevedo E. Síndrome de Moyamoya: heterogeneidade clínica. Comunicação oral no 10º Simpósio do Núcleo de Estudos de Doenças Vasculares Cerebrais da Sociedade Portuguesa de Medicina Interna. Porto, Portugal, 14 November, 2009.ORAL PRESENTATION.
52. Mello RAB, Pantarotto M, Estevinho F, Azevedo I, Soares M, Araújo A. Nova Classificação TMN para Estadiamento do Carcinoma do Pulmão de Não Pequenas Células (CPNPC) – Impacto nos Casos Diagnosticados em 2008 no IPOPGF. No XVI Congresso Brasileiro de Oncologia Clínica. Promovido pela Sociedade Brasileira de Oncologia Clínica (SBOC). 7 – 10 October 2009 - Fortaleza – CE, Brazil. POSTER PRESENTATION.
53. Mello RAB, Pantarotto M, Estevinho F, Azevedo I, Soares M, Araújo A. Cancro do Pulmão nos anos de 2004 – 2008: Casuística do IPOPGF. No XVI Congresso Brasileiro de Oncologia Clínica. Promovido pela Sociedade Brasileira de Oncologia Clínica (SBOC). 7 – 10 October 2009 - Fortaleza – CE, Brazil. POSTER PRESENTATION.
54. De Mello RA, Pais A, Carvalho T, Gervásio H. Carcinoma da Mama Inflamatório: Experiência do Instituto Português de Oncologia de Coimbra, Francisco Gentil (IPOC, FG). XVI Congresso Brasileiro de Oncologia Clínica. Promovido pela Sociedade Brasileira de Oncologia Clínica (SBOC). 7 – 10 October 2009 - Fortaleza – CE, Brazil. POSTER PRESENTATION.
55. De Mello RA, Pantarotto M, Marques M, Carvalho T, Gervásio H. Um caso clínico: Carcinoma lobular invasivo da mama direita e sarcoma do estroma da mama esquerda concomitante. Jornadas de Oncologia do IPOPORTO. Hotel Solverde, Espinho. 1 – 3 July 2009. Portugal. POSTER PRESENTATION.
56. Moura JFB, Albuquerque LMA, Mello RAB. Irradiação Esplênica em Pacientes com Doenças Linfo-proliferativa: Resultados e Revisão da Literatura. – 31ª Jornada Paulista de Radiologia. São Paulo – SP, 14 April 2001.Brazil. POSTER PRESENTATION.
57. Souza EF, Haquette EF, Oliveira LR, Gondim RLP, Mello RAB. Tumores de Tireóide no 1º. Ano do Serviço de Cirurgia de Cabeça e Pescoço do ICC / Hospital de Câncer, Fortaleza – CE. – XXXVII Congresso Anual do Centro Médico Cearense, October 2000. Brazil. ORAL PRESENTATION.

58. De Mello RA, Duarte AM, Bomfim FAC, Silva, AR.PBA: Método auxiliar para orientação da aprendizagem em anatomia humana. XVI Outubro Médico. Fortaleza – CE, Brazil. October, 2000. ORAL PRESENTATION.
59. De Mello RA. Hipertensos: a influência psicoemocional no quadro clínico do paciente – Comunicação oral no XIX Encontro Universitário de Iniciação à Pesquisa. Fortaleza-CE, Brazil, 8 - 10 November, 2000. ORAL PRESENTATION.
60. De Mello RA. Estudo da Atividade Citotóxica do Extrato Hidroalcoólico de Diferentes Partes da Phyllanthus Amarus. XVII Encontro Universitário de Iniciação à Pesquisa. Fortaleza-CE, November 12, 1999. Brazil. ORAL PRESENTATION.
61. De Mello RA. Avaliação do Potencial genotóxico do extrato hidro-alcóolico da Auxema oncocalix em camundongos Musmusculus. XVII Encontro Universitário de Iniciação à Pesquisa. Fortaleza-CE, November 12, 1999. Brazil. ORAL PRESENTATION

## Selected Speaking Engagements

1. Speaker for ASCO highlights-GI tumors, European School of Oncology, e-learning programmed, 22<sup>nd</sup> June 2023
2. Speaker for the ESO podcast – How to approach a breast cancer patient T2N0M0 who did not receive neoadjuvant chemotherapy after surgery, 19<sup>th</sup> September 2021, European School of Oncology (ESO), Milano, Italy
3. President for II UNIONCO – United International Oncology Congress, 5<sup>th</sup> December 2021, São Paulo, Brazil
4. Speaker Pan Hellenic Congress of Oncology & Molecular Targeted Therapies, Hotel Du Lac, Ioannina, Greece, 02 - 04 September 2021
5. Speaker for The 2021 scenario in targeted therapies for metastatic hepatobiliary and esophageal and gastric cancer, European School of Oncology, Milan, 13<sup>rd</sup> March 2021
6. Scientific Director for XXII CONCAN – Brazilian Congress of Cancerology, 25 – 26 September 2021, São Paulo, SP, Brazil
7. President for I UNIONCO – United International Oncology Congress, 3<sup>th</sup> December 2020, São Paulo, Brazil
8. Chair of the educational session: molecular targets and precision treatment, Brazilian Congress of Cancerology (CONCAN), Sheraton World Trade Center, São Paulo, Brazil, 26<sup>th</sup> September 2020.
9. Chair of the educational session: agnostic tumors, Brazilian Congress of Cancerology (CONCAN), Sheraton World Trade Center, São Paulo, Brazil, 26<sup>th</sup> September 2020.
10. Chair of the educational session: lung cancer stage III & IV, Brazilian Congress of Cancerology (CONCAN), Sheraton World Trade Center, São Paulo, Brazil, 25<sup>th</sup> September 2020.
11. Speaker: The role of EGFR inhibitors in stage IV non-small-cell lung cancer, Brazilian Congress of Cancerology (CONCAN), Sheraton World Trade Center, São Paulo, Brazil, 25<sup>th</sup> September 2020.

12. Speaker: Pancreatic cancer and gallbladder metastatic systemic treatment, E-Learning session, European School of Oncology (ESO), CME accredited, 14th July 2020, Milan, Italy
13. Speaker: The role of immune-checkpoints inhibitors for advanced colorectal cancer treatment, E-Learning session, European School of Oncology (ESO), CME accredited, 25th March 2020, Milan, Italy
14. Speaker: Trends in immunotherapy of gastrointestinal cancer. Invited speaker at 1st Southeastern European Immunotherapy (SEIC2019), Zagreb, Croatia, 11-12 October 2019.
15. Chair of the Educational Session Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies (De Mello RA, Lordick F, Muro K, Janjingian Y). 2019 American Society of Clinical Oncology (ASCO) annual meeting. Chicago, 31st May 2019 to 3rd June 2019.
16. Speaker at the 2019 American Society of Clinical Oncology (ASCO) annual meeting. Chicago, 31st May 2019 to 3rd June 2019. Oral Presentation: Should Immunotherapy Change the Practice for Esophageal and Gastric Cancer in the Near Future?
17. Speaker at ONCONET SUDOE. EUROPEAN NETWORK OF TRANSLATIONAL RESEARCH AND INNOVATION IN ONCOLOGY. Navarrabiomed 16th and 17th May 2019 - Molecular Biology, Cancer and Bioinformatics, Pamplona, Spain. Oral presentation: Predictive Biomarkers and cancer outcomes: what are the next steps?
18. Speaker at THE INTERNATIONAL GASTRIC CANCER CONGRESS IGCC 2019, Prague, 9 – 11th May 2019. Oral Presentation: Evidence for Immunotherapy Combined with Radiotherapy for Gastric and EG Junction Cancer.
19. Speaker for the What we will expect from novel therapies for esophageal and gastric malignancies. Educational Session Emerging Therapies in Upper Gastrointestinal Malignancies. American Society of Clinical Oncology Annual Meeting 1st June to 5th June 2018, Chicago, IL, USA.
20. Chair for the Educational Session Emerging Therapies in Upper Gastrointestinal Malignancies. American Society of Clinical Oncology Annual Meeting 1st June to 5th June 2018, Chicago, IL, USA.
21. Speaker at the Clinical Session “Update in systemic treatment for advanced head and neck squamous cell carcinoma”, Cearense School of Oncology, Ceará Cancer Institute, 22th December, 2017, Fortaleza, CE, Brazil.
22. Speaker at the Salvador MDT Breast Meeting. Lecture: Metastatic breast cancer – update in cyclin inhibitors clinical trials. Restaurante Casa de Teresa, 30 August 2017, Salvador, BA, Brazil. Sponsor: Novartis Brazil.
23. Session Discussion in Managing toxicities: Case based discussions. Harnessing the immune system for cancer therapy. ESMO 2016 Congress - Young Oncologist Masterclass. 09.10.2016, 14:15 - 17:15, Bern.
24. Anti-VEGF therapy in metastatic CRC, IV Annual Scientific Conference, Bulgarian Association of Medical Oncology, Marinela Hotel, Sofia, Bulgaria, 17 – 19 June 2016.
25. Resistance to anti-EGFR and ALK therapies, IV Annual Scientific Conference, Bulgarian Association of Medical Oncology, Marinela Hotel, Sofia, Bulgaria, 17 – 19 June 2016.

26. Anti-EGFR therapies in lung cancer, medical oncology residence program, Hospital Haroldo Juaçaba, Cancer Institute of Ceará, Fortaleza, Brazil, 23 May 2016, sponsored by AstraZeneca.
27. Pain management, NSAIs drugs and opioids, medical oncology residence program, Cearense School of Oncology, Cancer Institute of Ceará, Fortaleza, Brazil, 19 May 2016.
28. Treatment approaches for the operable gastric cancer: adjuvant chemotherapy, peri-operative chemotherapy or adjuvante radiochemotherapy, 2015 Xinhua International Surgical Forum, 21 November 2015, Shanghai, China.
29. Anorexia, cachexia and asthenia. Master in Palliative Care. Portuguese Catholic University, 28 November 2014, Porto, Portugal.
30. Insulin, anti-diabetes oral drugs. School of Medicine, University of Algarve. Faro, 22 April 2013. Portugal.
31. Polymorphic variants into angiogenesis pathways and non-small-cell lung cancer: overcoming a challenge. TM's 2nd World Cancer Online Conference. Target Meeting. January 8 – 11, 2013. 5702, Innsbruck St, Bellaire, TX, 77401, USA.
32. Insulin, anti-diabetes oral drugs, glucagon and endocrine drugs. School of Medicine, University of Algarve. Faro, 7 May 2012. Portugal.
33. Angiogenesis genetic polymorphisms and non-small-cell lung cancer: overcoming a challenge. 3th international conference on Biomarkers and Clinical Research Congress. Las Vegas, 2 - 4 July 2012. United States of America.
34. Lung cancer/cytotoxic pharmacology. School of Medicine, University of Algarve, October 27, 2011, Faro, Portugal.
35. Angiogenesis molecular pathways into non-small cell lung cancer tumor behavior. International conference on clinical research 2011. Theme: analyzation of novel approaches in Clinical Research. Marriot Hotel, San Francisco, California, USA. 5-6 July, 2011.
36. Basic Course in Human Anatomy at Federal University of Ceará, Fortaleza – CE, Brazil. April to November, 2000. Fortaleza, Ceará, Brazil.
37. Speaker of Basic Course in Human Anatomy at Federal University of Ceará, Fortaleza – CE, Brazil. April 10 – 18, 2000. Oral presentation. Total: 30h.
38. Speaker of Basic Course in Human Anatomy at Federal University of Ceará, Fortaleza – CE, Brazil. June 5 – 10, 2000. Oral presentation. Total: 40 h.
39. Speaker of Basic Course in Human Anatomy at Federal University of Ceará, Fortaleza – CE, Brazil. August 14 – 16, 2000. Oral presentation. Total: 30 h.
40. Speaker of Basic Course in Human Anatomy at Federal University of Ceará, Fortaleza – CE, Brazil. September 11 – 23, 2000. Oral presentation. Total: 30 h.

41. Speaker of Basic Course in Human Anatomy at Federal University of Ceará, Fortaleza – CE, Brazil. October 31 to November 16, 2000. Oral presentation. Total: 40 h.
42. Speaker of curso de videolaparoscopia terapêutica no trauma no III Congresso Norte-Nordeste de Trauma. Fortaleza-CE, Brazil, October 28, 2000. ORAL PRESENTATION

## Awards

1. Retinoblastoma and p53 protein expression in pre-malignant oral lesions and oral squamous cell carcinoma. First prize, poster presentation category. Évora Oncology Spring Meeting 2011. Évora Hotel, from March 31 to April 2, 2011. Évora, Portugal.
2. Fellowship: European Society for Medical Oncology (ESMO) Translational Research Unit visit at the Vall d'Hebron University Hospital, Barcelona – Spain, 27- 29 April, 2011.
3. Honor of Portuguese Society of Breast Cancer (Sociedade Portuguesa de Senologia) for the article published in 2012: de Mello RA, de Vasconcelos A, Ribeiro RA, Pousa I, Afonso N, Pereira D, Rodrigues H. Insights into p95 Her2 and breast cancer: molecular pathways and targeted therapies. *Recent Pat DNA Gene Seq.* 2012; 6 (1): 56 - 63.
4. Biography selected for the book *Who's Who in the World 2013 – Publication – Marquis Who's Who*. 30th edition, USA. ISBN: 978-0-8379-1150-2.
5. Biography selected for the book *2000 Outstanding Intellectuals of the 21st Century – 2013 – International Biographical Centre*, Cambridge, England.
6. ESMO Clinical Unit Visit Fellowship grant. Royal Marsden NHS Trust, London, from 2 September to 30 November 2013.
7. 3rd position among the best oral presentation: EPIGENETIC REGULATION OF CANCER SELF-RENEWAL DIFFERS BETWEEN PANCREATIC AND THYROID TUMORS. XIII Brazilian Congress of Surgical Oncology 25 a 28 de Outubro de 2017, Windsor Barra Hotel, Rio de Janeiro, RJ, Brazil.

## Books Edited

1. Editor-in-chief of *International Manual of Oncology Practice (iMOP): Principles of Oncology*. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer, New York, 2019. ISBN-13: 978-3030162443
2. Editor-in-chief of *International Manual of Oncology Practice (iMOP): Principles of Medical Oncology*. De Mello RA, Tavares A, Mountzios G: 1st Edition, Springer, New York, 2015. ISBN: 978 - 3 - 31921682 - 9.
3. Editor of *Tamoxifen concepts and cancer: new paradigms*. Nova publisher, New York, 31 Jan 2013. ISBN: 978-1-62081-520-5.

4. Editor of Vimentin concepts and molecular mechanisms. Nova publisher, New York, 15 April 2013. ISBN: 978-1624173592.

## Selected Books with Written Chapters

1. de Pádua, TC, Santos AJ, Tadokoro H, De Mello RA. Chapter 50 Brain metastasis. In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
2. Pozza DH, Gil-Mata S, Oliveira AF, Turner A, De Mello RA, Barros N. Chapter 48 Clinical Approaches to Adult Cancer Pain. In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
3. Borges AM, Santos AJ, Tadokoro H, De Mello RA. Chapter 43 Neoplastic Epidural Spinal Cord Compression In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
4. Muniz PC, Landgraf MM, Picon FS, Tadokoro H, De Mello RA, de Almeida MS. Chapter 42 Metabolic Disturbance. In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
5. Picon FS, Santos AJ, Tadokoro H, De Mello RA. Chapter 39 Primary Brain Tumors in Adults. In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
6. Kollár A, Aguiar Jr. PN, Forones NM, De Mello RA. Chapter 37 Gastrointestinal Stromal Tumor (GIST): Diagnosis and Treatment. In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
7. Silva GF, Guimarães DP, Tadokoro H, De Mello RA. Chapter 36 Bone Sarcoma In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
8. de Matos CM, de Araújo Filho IT, Fernandes, MV Barbosa DJM, André AT, Antoniou G, De Mello RA Chapter 35 Soft Tissue Sarcoma In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
9. Rocha JÁ, De Mello RA. Chapter 33 Parotid Gland Tumors In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
10. Gois Filho WLO, Vasconcelos JLM, Ferreira Junior, JW, Souza EF, Gondim RLP, de Oliveira ESC, De Mello RA. Chapter 32 Thyroid cancer In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
11. Justa RF, De Mello RA. Chapter 22 Ovarian Cancer In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3

12. Antoniou G, Koutsounas I, Kountourakis P, Pontas C, De Mello RA. Chapter 21 In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
13. Alvarenga TG, Muniz PC, Tadokoro H, De Mello RA, Forones NM. Chapter 20 Liver Cancer In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
14. Aguiar Jr. PN, Barreto CM, Forones NM, Tadokoro H, De Mello RA. Chapter 19 Small Intestine Cancer In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3
- 15.** Pádua TC, Tadokoro H, De Mello RA, Forones NM. Chapter 18 Anal Cancer In: International Manual of Oncology Practice (iMOP): Principles of Oncology. De Mello RA, Tavares A, Mountzios G: 2nd Edition, Springer Nature Switzerland AG 2019. ISBN 978-3-030-16244-3.

## Scientific Honors and Awards Jury Committee for Scientific Grants Agencies

1. Effective Member of the Scientific Ethical Committee, Nine of July University (UNINOVE), since 3<sup>rd</sup> march 2022, São Paulo, Brazil.
2. Member of the Jury committee for the PhD in oncology thesis. Faculty of Medicine, Nine of July University (UNINOVE), 4th December 2020, São Paulo, Brazil.
3. Member of the Jury committee for the PhD in radio-oncology thesis. Faculty of Medicine, University of São Paulo (USP), 17th November 2020, São Paulo, Brazil.
4. Member of the Jury committee for the master in oncology thesis. Fundação Pio XII, Hospital de Amor, Barretos, São Paulo, Brazil, 29th May 2020.
5. Member of the Jury committee for the prize: the best scientific published article in 2014. Research Support Department (Gabinete de Apoio à Intvestigação – GAI) – University of Coimbra, Portugal.
6. Member of the Jury committee for the research project grants application, 2015. Research Support Department (Gabinete de Apoio à Intvestigação – GAI) – University of Coimbra, Portugal.
7. Reviewer of research grants proposals for the Nacional Sciences Centre, Krakow, Poland, 2014.
8. Expert reviewer of research grants applications for The British Lung Foundation, London, United Kingdom, 2015.
9. Expert reviewer of research grants applications for at Netherlands Organization for Scientific Research (NOW), The Hague, Netherlands.
10. Expert reviewer of research grants for TRANSCAN-2 Joint Transnational Call, 2015.

11. Expert reviewer of research grant for Breakthrough Cancer Research Ireland, 2018
12. Expert reviewer of research grant for Singapore National Medical Research Council, 2018
13. Expert for the Foundation ARC pour la RECHERCHE sur le CANCER, Villejuif, France, since June 2018.
14. Practical Medical Residency Examination Committee at Federal University of São Paulo, Brazil, 2019.
15. Interview Panel Committee for the Medical Oncology Residency Examination at Federal University of São Paulo, Brazil, 2019.

## PI, Co-Investigation, and Selected Clinical Trials

1. “A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma” MK-3475-062-0180. Sponsor: Merck. Role: Principal Investigator. (Winner Research Budget US\$ 1,200,000.00 = R\$ 363,363.36).
2. MK3475-091 – A randomized phase 3 trial with anti-PD1 monoclonal antibody pembrolizumab versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS). Role: Principal Investigator. Sponsor: Merck Sharp & Dohme Corp.
3. Estudo Randomizado, Aberto de fase III de Sobrevida Global em Participantes Virgens de Tratamento com Câncer de Pulmão de Não Pequenas Células Avançado ou Metastático e PD-L1 Positivo comparando Pembrolizumabe e (MK-3475) à Quimioterapia baseada em Platina. Sponsor: Merck. Role: Sub-investigador.
4. Boehringer Biossimilar - BI 1302.5: Estudo clínico de fase III, multicêntrico, randomizado e duplo-cego para avaliar a eficácia e a segurança de BI 695502 associado à quimioterapia em comparação com Avastin® associado à quimioterapia em participantes com câncer de pulmão de células não pequenas e não escamosas avançado. Role: Sub-investigador.
5. A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo in Subjects with Extensive-Stage Disease Small-Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy. Sponsor: Bristol Myers Squibb. Role: Sub-investigador.
6. ARAMIS - BAYER: Estudo multinacional, randomizado, duplo-cego, controlado por placebo, de fase III de eficácia e segurança de ODM-201 em homens com câncer de próstata não metastático resistente à castração com alto risco de desenvolver metástases. Role: Sub-investigador.
7. Boston Biomedical - Brighter: Estudo Clínico de Fase III, Randomizado, Duplo-Cego e Controlado por Placebo de BBI608 em Combinação com Paclitaxel Semanal vs. Placebo em Combinação com Paclitaxel Semanal em Pacientes Adultos com Adenocarcinoma Gástrico e da Junção Gastroesofágica Avançado, Anteriormente Tratado. Role: Sub-investigador.
8. Avaliação dos níveis do Fator de Crescimento Epidérmico (EGF) em pacientes com adenocarcinoma de pulmão metastático da Rede Nacional de Pesquisa Clínica em Câncer (RNPPC). Coorte, prospectiva, translacional. Sponsor: Brazilian National Cancer Institute (INCA). Role: Sub-investigador.

9. Perfil Molecular do Adenocarcinoma de pulmão no Brasil – Adenonacional. Sponsor: INCA. Role: Sub-investigator.
10. Capecitabine and Tarceva in Advanced Lung Cancer (CAPITAL). Sponsor: Royal Marsden Hospital, London, UK. Role: Sub-investigator.
11. Prospective randomized controlled trial to investigate the effectiveness of inhalers for the relief of breathlessness in patients with lung cancer and COPD. Sponsor: Royal Marsden Hospital, London, UK. Role: Sub-investigator.
12. Study of Pleural effusions to Characterize signal transduction Kinase pathways in non-small cell lung cancer (NSCLC) and malignant mesothelioma. Sponsor: Royal Marsden Hospital, London, UK. Role: Sub-investigator.
13. A randomized study to investigate the effectiveness of acupuncture for the relief of dyspnoea in patients with non-small cell lung cancer and mesothelioma. Sponsor: Royal Marsden Hospital, London, UK. Role: Sub-investigator.
14. EQUALITY - Expression Quantitative trait Loci mapping In Tumors collected at bronchoscopy. Sponsor: Imperial College, London, UK. Role: Sub-investigator.

## Advisory Boards

1. Member of the gastrointestinal cancer advisory board for the European School of Oncology (ESO), since 2020. Milano, Italy.
2. Advisory board consultant, NSCLC immunotherapy patient flow, Merck Sharp and Dohme (MSD), 2017/2019. Zurich, Switzerland.
3. Advisory board consultant, ADT and prostate cancer, Zodiac Inc. 2016/2019. São Paulo, Brazil.
4. Advisory board consultant, Gastric cancer treatment with trastuzumab biosimilar, Pfizer, Inc., 2015/2018. Rome, Italy.

## Scientific Society Activities

1. Fellow Member of the Royal Society of Medicine, since 2021, London, United Kingdom
2. Head of Medical Oncology Section of the Brazilian Society of Cancerology, since 1<sup>st</sup> January 2021
3. Member of the British Medical Association, since 2021, London, United Kingdom
4. Fellow member of the American College of Physicians (FACP), since July 2017.
5. Faculty member of the College of the European School of Oncology (ESCO), since 15th July 2020
6. Full member of the American Society for Clinical Oncology (ASCO), since January 2011.

7. Member of the gastrointestinal cancer advisory board for the European School of Oncology (ESO), since Jan 2020.
8. Member of the Cancer Educational Committee (Gastrointestinal non-colorectal), ASCO, Alexandria, VA, USA, since June 2016 to June 2019.
9. Member of the Gastro-intestinal Faculty, European Society for Medical Oncology (ESMO) since June 2018 to June 2022.
10. Member of European Society for Medical Oncology (ESMO) since June 2010.
11. Full Member of Portuguese Society for Oncology (SPO) since April 2010.
12. Full member of Brazilian Society of Cancerology (SBC) since August 2014.
13. Full Member of Brazilian Society of Clinical Oncology (SBOC), since 2015.
14. Full member of Portuguese Association for Palliative Care (APCP), since 2014.
15. Effective member of Brazilian Society for Internal Medicine (SBCM) since November 2010.